期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 58, 期 2, 页码 212-216出版社
WILEY
DOI: 10.1111/j.1365-2125.2004.02117.x
关键词
Glivec (R); Gleevec (TM); imatinib mesylate; CGP74588; alpha(1)-acid glycoprotein
Aims To determine blood binding parameters of imatinib and its metabolite CGP74588 in humans and non-human species. Methods The blood distribution and protein binding of imatinib and CGP74588 were determined in vitro using C-14 labelled compounds. Results The mean fraction of imatinib in plasma (f(p)) was 45% in dog, 50% in mouse, 65% in rat, 70% in healthy humans and up to 92% in acute lymphatic leukaemia (AML) patients. Similarly, f(p) for CGP74588 was low in dog and monkey (30%), higher in rat, mouse and humans (70%) and highest in some AML patients (90%). The unbound fraction of imatinib and CGP74588 in plasma was lower in rat, mouse, healthy humans and AML patients (2.3-6.5% at concentrations less than or equal to 5000 ng ml(-1)) compared to monkey and dog (7.6-19%). Both compounds displayed high binding to human alpha(1)-acid glycoprotein. AML patients had a reduced haematocrit and showed greatest variability in their blood binding parameters. Conclusion Imatinib and CGP74588 displayed very similar blood binding parameters within all species/groups investigated. The five species clustered into two distinct groups with rat, mouse and humans being clearly different from dog and monkey. For both compounds, higher protein binding was associated with a decreased partitioning into blood cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据